Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

PD-1 immune checkpoint inhibitors have produced encouraging results in patients with
hepatocellular carcinoma (HCC). However, what determines resistance to anti–PD-1 …

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally
considered as low immune-reactive cancers that represent either limited infiltration of …

Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an
exhausted immune response. However, response rates remain limited, likely secondary to a …

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …

Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …